KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Sales and Divestitures (2018 - 2020)

Esperion Therapeutics' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $53587.0 for Q2 2020.

  • For Q2 2020, Gains from Sales and Divestitures rose 427.95% year-over-year to $53587.0; the TTM value through Jun 2020 reached $53587.0, up 427.95%, while the annual FY2019 figure was $17710.0, 415.27% up from the prior year.
  • Gains from Sales and Divestitures reached $53587.0 in Q2 2020 per ESPR's latest filing, up from $10089.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $53587.0 in Q2 2020 to a low of $1562.0 in Q1 2018.
  • Average Gains from Sales and Divestitures over 3 years is $11850.9, with a median of $6763.0 recorded in 2018.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 100.06% in 2019, then surged 427.95% in 2020.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $3437.0 in 2018, then skyrocketed by 415.27% to $17710.0 in 2019, then skyrocketed by 202.58% to $53587.0 in 2020.
  • Per Business Quant, the three most recent readings for ESPR's Gains from Sales and Divestitures are $53587.0 (Q2 2020), $10089.0 (Q1 2020), and $17710.0 (Q4 2019).